The First Results of Ruxolitinib Versus Best Available Therapy for Polycythemia Vera in Mongolia

被引：0
|
作者：
Gonchigdash, Chinbat [1 ]
Purevsuren, Baljinnyam [1 ]
Tungalag, Saruul [1 ]
Tungalagchimeg, Erdenechimeg [1 ]
Norov, Oyundelger [1 ]
机构：
[1] First Cent Hosp Mongolia, Ulaanbaatar, Mongolia
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷
关键词：
MPN; ruxolitinib; polycythemia vera; hydroxyurea;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MPN-374
引用
收藏
页码：S430 / S430
页数：1
相关论文
共 50 条
  • [41] Combination therapy with ruxolitinib and pegylated interferon alfa2a in newly diagnosed patients with polycythemia vera
    Sorensen, Anders Lindholm
    Skov, Vibe
    Kjaer, Lasse
    Bjorn, Mads Emil
    Eickhardt-Dalboge, Christina Schjellerup
    Larsen, Morten Kranker
    Nielsen, Claus H.
    Thomsen, Carsten
    Gjerdrum, Lise Mette Rahbek
    Knudsen, Trine Alma
    Ellervik, Christina
    Overgaard, Ulrik Malthe
    Andersen, Christen Lykkegaard
    Hasselbalch, Hans
    BLOOD ADVANCES, 2024, 8 (20) : 5416 - 5425
  • [42] PHASE 3 RANDOMIZED TRIAL OF MOMELOTINIB VERSUS BEST AVAILABLE THERAPY IN PATIENTS WITH MYELOFIBROSIS PREVIOUSLY TREATED WITH RUXOLITINIB: RESULTS OF THE SIMPLIFY-2 STUDY
    Verstovsek, S.
    Vannucchi, A. M.
    Platzbecker, U.
    Cervantes, F.
    Gupta, V.
    Lavie, D.
    Passamonti, F.
    Winton, E. F.
    Dong, H.
    Kawashima, J.
    Maltzman, J. D.
    Kiladjian, J-J.
    Harrison, C. N.
    HAEMATOLOGICA, 2017, 102 : 320 - 321
  • [43] Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study
    Sorensen, Anders Lindholm
    Mikkelsen, Stine Ulrik
    Knudsen, Trine Alma
    Bjorn, Mads Emil
    Andersen, Christen Lykkegaard
    Bjerrum, Ole Weis
    Brochmann, Nana
    Patel, Dustin Andersen
    Gjerdrum, Lise Mette Rahbek
    El Fassi, Daniel
    Kruse, Torben A.
    Larsen, Thomas Stauffer
    Mourits-Andersen, Hans Torben
    Nielsen, Claus Henrik
    Ellervik, Christina
    Pallisgaard, Niels
    Thomassen, Mads
    Kjaer, Lasse
    Skov, Vibe
    Hasselbach, Hans Carl
    HAEMATOLOGICA, 2020, 105 (09) : 2262 - 2272
  • [44] Efficacy and Safety of Single-Agent Ruxolitinib Therapy for Myelofibrosis and Polycythemia Vera: A Meta-Analysis
    Zhang, Shijia
    Wang, Yucai
    Sanchez, Larysa
    Duma, Narjust
    Chang, Victor
    BLOOD, 2015, 126 (23)
  • [45] Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera-myelofibrosis (PPV-MF) or post-essential thrombocythemia-myelofibrosis (PET-MF)
    Harrison, C. N.
    Kiladjian, J.
    Al-Ali, H. K.
    Gisslinger, H.
    Waltzman, R. J.
    Stalbovskaya, V.
    McQuitty, M.
    Hunter, D. S.
    Levy, R. S.
    Cervantes, F.
    Vannucchi, A. M.
    Barbui, T.
    Barosi, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (18)
  • [46] Firstline Treatment with Ruxolitinib Versus Best Available Therapy in Patients with Polycythemia Vera: Pre-Specified Interim Analysis of the Randomized Phase 2b Ruxobeat Clinical Trial of the German Study Group for Myeloproliferative Neoplasms (GSG-MPN)
    Koschmieder, Steffen
    Isfort, Susanne
    Teichmann, Lino L.
    Schafhausen, Philippe
    Heidel, Florian
    Hochhaus, Andreas
    Griesshammer, Martin
    Sockel, Katja
    Jost, Philipp
    Wolleschak, Denise
    Doehner, Konstanze
    Goethert, Joachim R.
    Radsak, Markus P.
    Augustin, Marinela
    Becker, Heiko
    Giagounidis, Aristoteles
    Schaich, Markus
    Klausmann, Martine
    Von Bubnoff, Nikolas
    Stegelmann, Frank
    Kortmann, Maike
    Frank, Julia
    Hellmich, Martin
    Bruemmendorf, Tim H.
    BLOOD, 2023, 142
  • [47] Cost-Effectiveness of Ruxolitinib Versus Best-Available Therapy for Medical Treatment of Myelofibrosis: Canadian Societal Perspective
    El Ouagari, Khalid
    Knight, Christopher John
    Mendelson, Estella T.
    BLOOD, 2012, 120 (21)
  • [48] Long-Term Efficacy and Safety Results From a Phase II Study of Ruxolitinib in Patients with Polycythemia Vera
    Verstovsek, Srdan
    Passamonti, Francesco
    Rambaldi, Alessandro
    Barosi, Giovanni
    Rosen, Peter J.
    He, Shui
    Contel, Nancy
    Mookerjee, Bijoyesh
    Rumi, Elisa
    Gattoni, Elisabetta
    Pieri, Lisa
    Cazzola, Mario
    Kantarjian, Hagop M.
    Barbui, Tiziano
    Vannucchi, Alessandro M.
    BLOOD, 2012, 120 (21)
  • [49] Long-Term Efficacy and Safety (5 Years) in RESPONSE, a Phase 3 Study Comparing Ruxolitinib (rux) with Best Available Therapy (BAT) in Hydroxyurea (HU)-Resistant/Intolerant Patients (pts) with Polycythemia Vera (PV)
    Kiladjian, Jean-Jacques
    Zachee, Pierre
    Hino, Masayuki
    Pane, Fabrizio
    Masszi, Tamas
    Harrison, Claire N.
    Mesa, Ruben A.
    Miller, Carole B.
    Passamonti, Francesco
    Durrant, Simon
    Griesshammer, Martin
    Kirito, Keita
    Besses, Carles
    Moiraghi, Beatriz
    Rumi, Elisa
    Rosti, Vittorio
    Blau, Igor W.
    Francillard, Nathalie
    Dong, Tuochuan
    Wroclawska, Monika
    Vannucchi, Alessandro M.
    Verstovsek, Srdan
    BLOOD, 2018, 132
  • [50] Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy
    Mesa, Ruben
    Verstovsek, Srdan
    Kiladjian, Jean-Jacques
    Griesshammer, Martin
    Masszi, Tamas
    Durrant, Simon
    Passamonti, Francesco
    Harrison, Claire N.
    Pane, Fabrizio
    Zachee, Pierre
    Zhen, Huiling
    Jones, Mark M.
    Parasuraman, Shreekant
    Li, Jingjin
    Cote, Isabelle
    Habr, Dany
    Vannucchi, Alessandro M.
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2016, 97 (02) : 192 - 200
12345